Trials / Terminated
TerminatedNCT01298830
GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- CellMed AG, a subsidiary of BTG plc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the safety of GLP-1 CellBeads® in patients with space-occupying intracerebral hemorrhage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLP-1 CellBeads | GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period. |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2011-02-18
- Last updated
- 2013-03-26
Locations
6 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01298830. Inclusion in this directory is not an endorsement.